Please login to the form below
6
Revenue 2017Remicade
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Remicade was produced by Johnson & Johnson, Mitsubishi Tanabe Pharma and Merck & Co..
ViiV’s two-drug HIV combo backed by CHMP
Sandoz’Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.
Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal
This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera.
The good, the bad and the ugly
Another top-selling drug also experienced decline for similar reasons: J&J’s Remicade - still in the top 10 best-selling products of 2017 - fell back by 7.5% due to
J&J files would-be prostate cancer blockbuster in US
up and the threat of biosimilar competition to big-selling biologic drugs such as Remicade (infliximab) is becoming ‘more measured’.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Sudler London - Account Director
-
Competitive
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Sudler London - Senior Medical Writer
-
Competitive
-
Systematic Review Lead- London
-
Negotiable
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Account Director or Senior Account Director
-
Salary TBC
-
Senior Medical Writer
-
Salary is DOE
-
Account Manager
-
Negotiable
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
Subscribe to our email news alerts
- Lucid limbers up for second annual sports day
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- Hanover Health launches award, Firstlight spins off healthcare arm and more
- J&J files ‘breakthrough’ bladder cancer drug in US
- Boehringer’s Corsico to be new GSK drug dev leader
- More tell, less sell: HCP-centric comms
PMHub
PharmiWeb Solutions
PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
